[
    "r removed (-). The efficiency of M9-induced reprogramming was assigned as \"1\". DMSO was used as negative control. <figref idrefs=\"f0019\">FIG. 4C</figref> shows a schematic diagram (top panel) of the <i>Sox2</i> regulatory regions SRRl, SRR2 and promoter (Pro). The bottom left panel of <figref idrefs=\"f0019\">FIG. 4C</figref> graphically illustrates the relative binding of Elkl at the <i>Sox2</i> SRRl, SRR2 and promoter regulatory regions at the indicated time points. The bottom right panel of <figref idrefs=\"f0019\">FIG. 4C</figref> shows the relative binding of Gli2 at the <i>Sox2</i> SRR1, SRR2 and promoter regulatory regions at the indicated time points. Relative binding was relative to binding by an IgG control. TSS refers to transcription starting site, and Pro refers to promoter. <figref idrefs=\"f0019\">FIG. 4D</figref> graphically illustrates the relative reprogramming efficiency assessed when <i>Elkl</i> expression was knocked down by <i>Elkl</i> shRNA at the indicated time points (day 1, day 4, or day 8). <figref idrefs=\"f0019\">FIG. 4E</figref> graphically illustrates the relative reprogramming efficiency assessed when <i>Gli2</i> expression was knocked down by <i>Gli2</i> shRNA at the indicated time points (day 1, day 4, or day 8). <figref idrefs=\"f0020\">FIG. 4F</figref> graphically illustrates the relative reprogramming efficiency assessed when <i>Elkl</i> is over-expressed or when <i>Gli2</i> is over-expressed. The acronyms have the following meaning: wt, wild type; KD, shRNA-mediated gene knockdown; <i>o</i>/<i>e,</i> overexpression. <figref idrefs=\"f0020\">FIG. 4G</figref> is a schematic diagram of a model interpreting M9-induced neural reprogramming through activating intrinsic neural program. Error bars, s.d., based on triplicates for <figref idrefs=\"f0018 f0019 f0020\">FIG. 4A-F</figref>. <sup>\u2217</sup>, <i>P</i>&lt;<i>0.01.</i> <figref idrefs=\"f0021\">FIG. 4H</figref> shows images ciNSLC-derived neurons illustrating the morphology of the neurons at day 3 (left), day 6 (middle), and day 10 (right) of differentiation. Scale bar is 10 \u00b5m. <figref idrefs=\"f0022\">FIG. 4I</figref> shows images of images ciNSLC-derived neurons illustrating differentiation into Map-positive and NeuN-positive neurons. Scale bar is 100 \u00b5m. <figref idrefs=\"f0022\">FIG. 4J</figref> shows images of images ciNSLC-derived neurons illustrating differentiation into vGLUT1-positive and Map2-positive neurons. Scale bar is 50 \u00b5m. <figref idrefs=\"f0022\">FIG. 4K</figref> shows images of images ciNSLC-derived neurons illustrating differentiation into GABA-positive and Map2-positive neurons. Scale bar is 50 \u00b5m. <figref idrefs=\"f0022\">FIG. 4L</figref> shows images of images ciNSLC-derived neurons illustrating differentiation into Synapsin-positive neurons. Scale bar is 50 \u00b5m.</li><li><figref idrefs=\"f0023\">FIG. 5A-5E</figref> illustrates the membrane properties and synaptic responses of ciNSLC-derived neurons. <figref idrefs=\"f0023\">FIG. 5A</figref> shows current traces of ciNSL",
    "nyi Biotec;</p><p id=\"p0022\" num=\"0022\">The BMP type I receptor ALK2/3 inhibitor can be used in various concentrations. For example, the BMP type I receptor ALK2/3 inhibitor can be employed at a concentration of 10 nanomolar to 500 nanomolar, or 50 nanomolar to 200 nanomolar, or 100 nanomolar in a solution. In a dry formulation, BMP type I receptor ALK2/3 inhibitors can be present in amounts of 0.01 mg to 2000 mg, or 0.1 mg to 1000 mg, or 1 mg to 500 mg.</p><p id=\"p0023\" num=\"0023\">Cells can be incubated in a medium containing LDN-193189) for varying amounts of time, e.g. until at least some of the cells express neural progenitor markers such as Sox2<sup>+</sup> and/or Nkx6.1<sup>+</sup>. The incubation time can vary, for example, from 1 day to 30 days, or from 2 days to 25 days, or from 4 days to 20 days, or 10 days.</p><heading id=\"h0007\"><b>TGF-beta Inhibitors</b></heading><p id=\"p0024\" num=\"0024\">As illustrated herein use of a transforming growth factor-beta (TGF-\u03b2) inhibitor can facilitate conversion of differentiated cells into the neuronal cell lineage. A TGF-\u03b2 family member elicits its responses through a variety of cell surface receptors that activate Smad protein signaling cascades. The TFG-\u03b2 used herein is 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (also known as A83-01 available from Tocris Bioscience; a selective inhibitor of TGF-\u03b2 type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values can, e.g., be 12, 45 and 7.5 nM respectively).<!-- EPO <DP n=\"12\"> --></p><p id=\"p0025\" num=\"0025\">The TGF-beta inhibitor can be employed in the compositions and methods described herein in a variety of amounts and/or concentrations. For example, the TGF-beta inhibitor can be employed at a concentration of 0.05 micromolar to 5 micromolar, or 0.1 micromolar to 1 micromolar, or 0.5 micromolar in a solution. In a dry formulation, the TGF-beta inhibitor can be present in amounts of 0.01 mg to 1000 mg, or 0.05 mg to 500 mg, or 0.1 mg to 50 mg.</p><p id=\"p0026\" num=\"0026\">The time of contacting or mixing TGF-beta inhibitor with a population of cells (to generate neural cells) can vary, for example, from 1 day to 30 days, or from 2 days to 25 days, or from 3 days to 20 days, or from 5 days to 15 days, or from 7 days to 14 days, or 10 days.</p><heading id=\"h0008\"><b>WNT Activators</b></heading><p id=\"p0027\" num=\"0027\">As illustrated herein use of a WNT activator can facilitate conversion of differentiated cells into the neuronal cell lineage.</p><p id=\"p0028\" num=\"0028\">The WNT signaling pathway includes a series of events that occur when a WNT protein binds to a cell-surface receptor of a Frizzled receptor family member. Such events result in the activation of Dishevelled family proteins which inhibit a complex of proteins that includes axin, GSK-3, and the protein APC to degrade intracellular beta-catenin. The resulting enriched nuclear beta-catenin enhances transcripti"
]